孤立性骨肿瘤影像报告与数据系统(BTI-RADS):系统化影像评估与综合报告方法的初步评价
基于230例经组织学确诊的骨肿瘤患者的前瞻性试验数据回顾性分析CT与MR影像特征,识别出7项良性指标(平均良性频率94%)、6项次要恶性指标(平均恶性频率60.5%)和3项主要恶性指标(Lodwick-Madewell III级、侵袭性骨膜反应、可疑转移性疾病,平均恶性频率82.4%)。据此提出BTI-RADS,其可重复性为fair(kappa=0.67),I、II、III、IV类的平均恶性频率分别为0%、2.2%、20.1%和71%。
要点
- BTI-RADS将孤立性骨肿瘤分为I-IV类,恶性频率依次升高(0%、2.2%、20.1%、71%)。
- Lodwick-Madewell III级、侵袭性骨膜反应、可疑转移性疾病为主要恶性指标,平均恶性频率82.4%。
- 7项良性指标平均良性频率94%,6项次要恶性指标平均恶性频率60.5%。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Identify the most pertinent imaging features for solitary bone tumor characterization using a multimodality approach and propose a systematic evaluation system.
METHODS: Data from a prospective trial, including 230 participants with histologically confirmed bone tumors, typical "do not touch" lesions, and stable chondral lesions, were retrospectively evaluated. Clinical data, CT, and MR imaging features were analyzed by a musculoskeletal radiologist blinded to the diagnosis using a structured report. The benign-malignant distribution of lesions bearing each image feature evaluated was compared to the benign-malignant distribution in the study sample. Benign and malignant indicators were identified. Two additional readers with different expertise levels independently evaluated the study sample.
RESULTS: The sample included 140 men and 90 women (mean age 40.7 ± 18.3 years). The global benign-malignant distribution was 67-33%. Seven imaging features reached the criteria for benign indicators with a mean frequency of benignancy of 94%. Six minor malignant indicators were identified with a mean frequency of malignancy of 60.5%. Finally, three major malignant indicators were identified (Lodwick-Madewell grade III, aggressive periosteal reaction, and suspected metastatic disease) with a mean frequency of malignancy of 82.4%. A bone tumor imaging reporting and data system (BTI-RADS) was proposed. The reproducibility of the BTI-RADS was considered fair (kappa = 0.67) with a mean frequency of malignancy in classes I, II, III, and IV of 0%, 2.2%, 20.1%, and 71%, respectively.
CONCLUSION: BTI-RADS is an evidence-based systematic approach to solitary bone tumor characterization with a fair reproducibility, allowing lesion stratification in classes of increasing malignancy frequency.
TRIAL REGISTRATION: Clinical trial number NCT02895633 .
KEY POINTS: • The most pertinent CT and MRI criteria allowing bone tumor characterization were defined and presented. • Lodwick-Madewell grade III, aggressive periosteal reaction, and suspected metastatic disease should be considered major malignant indicators associated with a frequency of malignancy over 75%. • The proposed evidence-based multimodality reporting system stratifies solitary bone tumors in classes with increasing frequencies of malignancy.
引用
- Ribeiro GJ, Gillet R, Hossu G, et al. Solitary bone tumor imaging reporting and data system (BTI-RADS): initial assessment of a systematic imaging evaluation and comprehensive reporting method. Eur Radiol. 2021. PMID: 33765161. doi:10.1007/s00330-021-07745-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。